Share Price and Basic Stock Data
Last Updated: December 12, 2025, 6:47 am
| PEG Ratio | -2.45 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
IOL Chemicals & Pharmaceuticals Ltd operates within the pharmaceuticals sector, focusing on producing a range of chemical and pharmaceutical products. The company’s revenue trajectory has been somewhat inconsistent, with sales figures fluctuating over recent quarters. For instance, sales stood at ₹587 Cr in March 2023 but dipped to ₹520 Cr by December 2023. This trend indicates some volatility, which could be attributed to market conditions or operational challenges. However, the company did report a total sales figure of ₹2,217 Cr for FY 2023, slightly lower than the previous year’s ₹2,184 Cr. This marginal decline, coupled with a trailing twelve-month (TTM) revenue of ₹2,129 Cr, suggests that while growth may be stalling, the company is still generating significant revenue. Investors might note that the pharmaceutical industry typically faces cyclical demand, making it crucial for IOL to adapt swiftly to market dynamics.
Profitability and Efficiency Metrics
When examining IOL’s profitability, the operating profit margin (OPM) reveals a mixed performance. The OPM was reported at 11% for the latest quarter, down from 12% in the previous year. This decline may raise concerns about cost management and pricing power, particularly as expenses have also seen fluctuations. The net profit for FY 2023 was ₹140 Cr, a drop from ₹166 Cr in FY 2022, indicating a tightening profit landscape. Efficiency ratios such as the return on equity (ROE) stood at 6.13%, which is relatively low compared to industry standards. Additionally, the return on capital employed (ROCE) at 8.86% suggests that capital is not being utilized as effectively as it could be. Investors should be cautious, as these profitability metrics may hinder the company’s ability to reinvest for growth or return value to shareholders.
Balance Sheet Strength and Financial Ratios
IOL’s balance sheet displays a relatively strong position, with total reserves rising to ₹1,629 Cr, indicating a solid foundation for future operations. The company reported borrowings of just ₹117 Cr, reflecting a low debt-to-equity ratio of 0.06, which suggests that IOL is not heavily reliant on external financing. This low leverage gives the company considerable financial flexibility. However, the interest coverage ratio (ICR) of 15.22x is impressive, indicating that earnings are more than sufficient to cover interest obligations. Yet, the declining book value per share from ₹274.49 in FY 2024 to ₹57.49 in FY 2025 raises questions about shareholder equity erosion. Investors might want to keep an eye on how well IOL manages its capital and expenses, especially in light of its fluctuating revenues.
Shareholding Pattern and Investor Confidence
The shareholding structure of IOL Chemicals reflects a significant level of promoter confidence, with promoters holding 52.62% of the company. This stake could be interpreted as a positive sign, indicating that those closest to the company are committed to its long-term success. However, foreign institutional investors (FIIs) have recently reduced their stake to 2.25%, down from a peak of 3.54%, which could imply waning interest from international investors. Domestic institutional investors (DIIs) hold a negligible 0.05%, which raises questions about institutional confidence in the company’s future prospects. The overall number of shareholders decreased from 1,43,327 in December 2022 to 1,36,129, revealing a potential decrease in retail interest. This trend could suggest that investors are cautious, possibly due to the company’s inconsistent performance and profitability metrics.
Outlook, Risks, and Final Insight
Looking ahead, IOL Chemicals faces both opportunities and challenges. On one hand, its strong balance sheet and low debt position provide a cushion against economic fluctuations. On the other hand, the declining profitability metrics and fluctuating sales figures pose significant risks. Investors should be wary of the company’s ability to maintain margins in a competitive market, especially given the pressures from rising costs and pricing pressures. Moreover, the declining interest from institutional investors could reflect broader market sentiment about the company’s growth prospects. As such, potential investors might find it prudent to monitor IOL’s strategic initiatives, operational efficiencies, and market adaptations closely. The pharmaceutical sector can be highly volatile, and while IOL has strengths, the risks cannot be overlooked in a rapidly changing environment.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of IOL Chemicals & Pharmaceuticals Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 141 Cr. | 112 | 239/84.3 | 31.3 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,246 Cr. | 390 | 479/192 | 87.9 | 24.3 | 0.17 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 33.0 Cr. | 44.5 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 43.8 Cr. | 29.9 | 31.0/17.0 | 104 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,461.38 Cr | 1,157.79 | 51.81 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
All Competitor Stocks of IOL Chemicals & Pharmaceuticals Ltd
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 565 | 541 | 523 | 587 | 563 | 545 | 520 | 504 | 502 | 526 | 523 | 528 | 552 |
| Expenses | 509 | 510 | 480 | 491 | 490 | 481 | 476 | 454 | 452 | 484 | 476 | 465 | 490 |
| Operating Profit | 56 | 32 | 43 | 96 | 73 | 64 | 44 | 50 | 51 | 42 | 47 | 63 | 62 |
| OPM % | 10% | 6% | 8% | 16% | 13% | 12% | 9% | 10% | 10% | 8% | 9% | 12% | 11% |
| Other Income | 5 | 5 | 7 | 9 | 7 | 7 | 8 | 8 | 7 | 6 | 4 | 5 | 7 |
| Interest | 3 | 4 | 5 | 5 | 4 | 4 | 4 | 3 | 2 | 4 | 4 | 4 | 4 |
| Depreciation | 11 | 11 | 12 | 12 | 14 | 16 | 16 | 16 | 17 | 18 | 19 | 19 | 20 |
| Profit before tax | 47 | 22 | 33 | 88 | 62 | 51 | 32 | 38 | 39 | 26 | 28 | 45 | 46 |
| Tax % | 25% | 28% | 27% | 25% | 25% | 26% | 28% | 25% | 24% | 26% | 26% | 30% | 25% |
| Net Profit | 35 | 16 | 24 | 65 | 46 | 38 | 23 | 28 | 30 | 19 | 21 | 32 | 34 |
| EPS in Rs | 1.19 | 0.53 | 0.82 | 2.22 | 1.57 | 1.29 | 0.79 | 0.96 | 1.01 | 0.65 | 0.70 | 1.08 | 1.16 |
Last Updated: August 20, 2025, 8:55 am
Below is a detailed analysis of the quarterly data for IOL Chemicals & Pharmaceuticals Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 552.00 Cr.. The value appears strong and on an upward trend. It has increased from 528.00 Cr. (Mar 2025) to 552.00 Cr., marking an increase of 24.00 Cr..
- For Expenses, as of Jun 2025, the value is 490.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 465.00 Cr. (Mar 2025) to 490.00 Cr., marking an increase of 25.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 62.00 Cr.. The value appears to be declining and may need further review. It has decreased from 63.00 Cr. (Mar 2025) to 62.00 Cr., marking a decrease of 1.00 Cr..
- For OPM %, as of Jun 2025, the value is 11.00%. The value appears to be declining and may need further review. It has decreased from 12.00% (Mar 2025) to 11.00%, marking a decrease of 1.00%.
- For Other Income, as of Jun 2025, the value is 7.00 Cr.. The value appears strong and on an upward trend. It has increased from 5.00 Cr. (Mar 2025) to 7.00 Cr., marking an increase of 2.00 Cr..
- For Interest, as of Jun 2025, the value is 4.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 4.00 Cr..
- For Depreciation, as of Jun 2025, the value is 20.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 19.00 Cr. (Mar 2025) to 20.00 Cr., marking an increase of 1.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 46.00 Cr.. The value appears strong and on an upward trend. It has increased from 45.00 Cr. (Mar 2025) to 46.00 Cr., marking an increase of 1.00 Cr..
- For Tax %, as of Jun 2025, the value is 25.00%. The value appears to be improving (decreasing) as expected. It has decreased from 30.00% (Mar 2025) to 25.00%, marking a decrease of 5.00%.
- For Net Profit, as of Jun 2025, the value is 34.00 Cr.. The value appears strong and on an upward trend. It has increased from 32.00 Cr. (Mar 2025) to 34.00 Cr., marking an increase of 2.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 1.16. The value appears strong and on an upward trend. It has increased from 1.08 (Mar 2025) to 1.16, marking an increase of 0.08.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: September 18, 2025, 4:17 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 564 | 385 | 580 | 711 | 983 | 1,685 | 1,894 | 1,967 | 2,184 | 2,217 | 2,133 | 2,079 | 2,129 |
| Expenses | 468 | 373 | 529 | 608 | 863 | 1,276 | 1,321 | 1,375 | 1,927 | 1,990 | 1,901 | 1,877 | 1,915 |
| Operating Profit | 96 | 11 | 51 | 102 | 120 | 410 | 574 | 592 | 257 | 227 | 232 | 202 | 214 |
| OPM % | 17% | 3% | 9% | 14% | 12% | 24% | 30% | 30% | 12% | 10% | 11% | 10% | 10% |
| Other Income | 1 | 1 | 1 | 1 | 6 | 10 | 16 | 24 | 17 | 25 | 30 | 22 | 22 |
| Interest | 60 | 59 | 61 | 68 | 64 | 51 | 21 | 6 | 8 | 16 | 16 | 15 | 17 |
| Depreciation | 32 | 29 | 30 | 30 | 30 | 32 | 36 | 39 | 43 | 46 | 63 | 72 | 75 |
| Profit before tax | 5 | -75 | -39 | 6 | 31 | 336 | 533 | 571 | 223 | 189 | 183 | 138 | 144 |
| Tax % | 35% | -12% | 4% | 21% | 12% | 30% | 32% | 22% | 26% | 26% | 26% | 27% | |
| Net Profit | 3 | -67 | -40 | 5 | 28 | 237 | 361 | 445 | 166 | 140 | 135 | 101 | 105 |
| EPS in Rs | 0.23 | -2.80 | -1.42 | 0.17 | 0.99 | 8.32 | 12.70 | 15.15 | 5.64 | 4.77 | 4.61 | 3.44 | 3.59 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 5% | 8% | 14% | 17% | 22% | 23% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -2333.33% | 40.30% | 112.50% | 460.00% | 746.43% | 52.32% | 23.27% | -62.70% | -15.66% | -3.57% | -25.19% |
| Change in YoY Net Profit Growth (%) | 0.00% | 2373.63% | 72.20% | 347.50% | 286.43% | -694.11% | -29.05% | -85.97% | 47.03% | 12.09% | -21.61% |
IOL Chemicals & Pharmaceuticals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 2% |
| 3 Years: | -2% |
| TTM: | 3% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | -22% |
| 3 Years: | -17% |
| TTM: | -11% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 21% |
| 5 Years: | -8% |
| 3 Years: | 10% |
| 1 Year: | 4% |
| Return on Equity | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 14% |
| 3 Years: | 8% |
| Last Year: | 6% |
Last Updated: September 5, 2025, 7:50 am
Balance Sheet
Last Updated: December 10, 2025, 2:52 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 29 | 48 | 56 | 56 | 56 | 57 | 57 | 59 | 59 | 59 | 59 | 59 | 59 |
| Reserves | 160 | 160 | 129 | 132 | 160 | 417 | 757 | 1,202 | 1,332 | 1,448 | 1,553 | 1,629 | 1,692 |
| Borrowings | 377 | 400 | 453 | 447 | 422 | 284 | 59 | 3 | 44 | 80 | 33 | 117 | 159 |
| Other Liabilities | 175 | 94 | 135 | 182 | 214 | 184 | 297 | 347 | 526 | 434 | 600 | 577 | 503 |
| Total Liabilities | 741 | 702 | 772 | 817 | 852 | 942 | 1,170 | 1,610 | 1,960 | 2,021 | 2,244 | 2,382 | 2,413 |
| Fixed Assets | 411 | 403 | 400 | 374 | 406 | 412 | 469 | 512 | 561 | 751 | 933 | 1,170 | 1,142 |
| CWIP | 33 | 4 | 4 | 21 | 7 | 27 | 19 | 48 | 105 | 90 | 101 | 22 | 64 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 20 | 21 | 21 | 21 |
| Other Assets | 297 | 295 | 369 | 422 | 439 | 503 | 682 | 1,048 | 1,292 | 1,159 | 1,190 | 1,168 | 1,185 |
| Total Assets | 741 | 702 | 772 | 817 | 852 | 942 | 1,170 | 1,610 | 1,960 | 2,021 | 2,244 | 2,382 | 2,413 |
Below is a detailed analysis of the balance sheet data for IOL Chemicals & Pharmaceuticals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 59.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 59.00 Cr..
- For Reserves, as of Sep 2025, the value is 1,692.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,629.00 Cr. (Mar 2025) to 1,692.00 Cr., marking an increase of 63.00 Cr..
- For Borrowings, as of Sep 2025, the value is 159.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 117.00 Cr. (Mar 2025) to 159.00 Cr., marking an increase of 42.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 503.00 Cr.. The value appears to be improving (decreasing). It has decreased from 577.00 Cr. (Mar 2025) to 503.00 Cr., marking a decrease of 74.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 2,413.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2,382.00 Cr. (Mar 2025) to 2,413.00 Cr., marking an increase of 31.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 1,142.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,170.00 Cr. (Mar 2025) to 1,142.00 Cr., marking a decrease of 28.00 Cr..
- For CWIP, as of Sep 2025, the value is 64.00 Cr.. The value appears strong and on an upward trend. It has increased from 22.00 Cr. (Mar 2025) to 64.00 Cr., marking an increase of 42.00 Cr..
- For Investments, as of Sep 2025, the value is 21.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 21.00 Cr..
- For Other Assets, as of Sep 2025, the value is 1,185.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,168.00 Cr. (Mar 2025) to 1,185.00 Cr., marking an increase of 17.00 Cr..
- For Total Assets, as of Sep 2025, the value is 2,413.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,382.00 Cr. (Mar 2025) to 2,413.00 Cr., marking an increase of 31.00 Cr..
Notably, the Reserves (1,692.00 Cr.) exceed the Borrowings (159.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -281.00 | -389.00 | -402.00 | -345.00 | -302.00 | 126.00 | 515.00 | 589.00 | 213.00 | 147.00 | 199.00 | 85.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 32 | 31 | 55 | 58 | 54 | 43 | 52 | 56 | 79 | 83 | 81 | 90 |
| Inventory Days | 190 | 279 | 201 | 201 | 109 | 66 | 64 | 98 | 95 | 77 | 111 | 95 |
| Days Payable | 119 | 92 | 102 | 115 | 83 | 42 | 62 | 79 | 95 | 74 | 123 | 112 |
| Cash Conversion Cycle | 103 | 218 | 154 | 144 | 80 | 67 | 55 | 74 | 79 | 86 | 69 | 73 |
| Working Capital Days | -5 | 59 | 39 | 36 | 23 | 43 | 46 | 66 | 71 | 72 | 71 | 58 |
| ROCE % | 11% | -3% | 4% | 12% | 15% | 56% | 68% | 54% | 18% | 14% | 12% | 9% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Motilal Oswal Nifty Microcap 250 Index Fund | 25,342 | 0.2 | 1.15 | 25,342 | 2025-04-22 17:25:30 | 0% |
| Motilal Oswal S&P BSE Healthcare ETF | 243 | 0.12 | 0.01 | 243 | 2025-04-22 17:25:30 | 0% |
| Groww Nifty Total Market Index Fund | 65 | 0.01 | 0 | 65 | 2025-04-22 17:25:30 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
|---|---|---|---|---|
| FaceValue | 2.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 3.44 | 22.90 | 23.70 | 28.56 |
| Diluted EPS (Rs.) | 3.44 | 22.90 | 23.70 | 28.56 |
| Cash EPS (Rs.) | 5.90 | 33.61 | 31.56 | 35.93 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 57.49 | 274.49 | 256.81 | 237.15 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 57.49 | 274.49 | 256.81 | 237.15 |
| Revenue From Operations / Share (Rs.) | 70.83 | 363.27 | 377.64 | 372.00 |
| PBDIT / Share (Rs.) | 7.65 | 44.40 | 42.80 | 49.45 |
| PBIT / Share (Rs.) | 5.20 | 33.68 | 34.94 | 42.08 |
| PBT / Share (Rs.) | 4.70 | 30.94 | 32.13 | 38.30 |
| Net Profit / Share (Rs.) | 3.44 | 22.90 | 23.70 | 28.56 |
| NP After MI And SOA / Share (Rs.) | 3.44 | 22.90 | 23.70 | 28.56 |
| PBDIT Margin (%) | 10.80 | 12.22 | 11.33 | 13.29 |
| PBIT Margin (%) | 7.34 | 9.27 | 9.25 | 11.31 |
| PBT Margin (%) | 6.63 | 8.51 | 8.50 | 10.29 |
| Net Profit Margin (%) | 4.86 | 6.30 | 6.27 | 7.67 |
| NP After MI And SOA Margin (%) | 4.86 | 6.30 | 6.27 | 7.67 |
| Return on Networth / Equity (%) | 5.98 | 8.34 | 9.22 | 12.04 |
| Return on Capital Employeed (%) | 8.61 | 11.74 | 13.09 | 17.05 |
| Return On Assets (%) | 4.24 | 5.98 | 6.88 | 8.54 |
| Total Debt / Equity (X) | 0.06 | 0.00 | 0.05 | 0.03 |
| Asset Turnover Ratio (%) | 0.89 | 0.99 | 1.11 | 0.00 |
| Current Ratio (X) | 1.89 | 2.00 | 2.02 | 2.11 |
| Quick Ratio (X) | 1.30 | 1.24 | 1.30 | 1.31 |
| Inventory Turnover Ratio (X) | 5.29 | 3.82 | 4.18 | 0.00 |
| Dividend Payout Ratio (NP) (%) | 23.23 | 21.83 | 16.88 | 21.00 |
| Dividend Payout Ratio (CP) (%) | 13.56 | 14.87 | 12.68 | 16.69 |
| Earning Retention Ratio (%) | 76.77 | 78.17 | 83.12 | 79.00 |
| Cash Earning Retention Ratio (%) | 86.44 | 85.13 | 87.32 | 83.31 |
| Interest Coverage Ratio (X) | 15.22 | 16.19 | 15.26 | 35.02 |
| Interest Coverage Ratio (Post Tax) (X) | 7.85 | 9.35 | 9.45 | 22.91 |
| Enterprise Value (Cr.) | 1705.42 | 1979.48 | 1718.71 | 1979.92 |
| EV / Net Operating Revenue (X) | 0.82 | 0.92 | 0.77 | 0.90 |
| EV / EBITDA (X) | 7.59 | 7.59 | 6.84 | 6.82 |
| MarketCap / Net Operating Revenue (X) | 0.86 | 0.99 | 0.74 | 0.95 |
| Retention Ratios (%) | 76.76 | 78.16 | 83.11 | 78.99 |
| Price / BV (X) | 1.06 | 1.32 | 1.10 | 1.49 |
| Price / Net Operating Revenue (X) | 0.86 | 0.99 | 0.74 | 0.95 |
| EarningsYield | 0.05 | 0.06 | 0.08 | 0.08 |
After reviewing the key financial ratios for IOL Chemicals & Pharmaceuticals Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. It has decreased from 10.00 (Mar 24) to 2.00, marking a decrease of 8.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 3.44. This value is below the healthy minimum of 5. It has decreased from 22.90 (Mar 24) to 3.44, marking a decrease of 19.46.
- For Diluted EPS (Rs.), as of Mar 25, the value is 3.44. This value is below the healthy minimum of 5. It has decreased from 22.90 (Mar 24) to 3.44, marking a decrease of 19.46.
- For Cash EPS (Rs.), as of Mar 25, the value is 5.90. This value is within the healthy range. It has decreased from 33.61 (Mar 24) to 5.90, marking a decrease of 27.71.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 57.49. It has decreased from 274.49 (Mar 24) to 57.49, marking a decrease of 217.00.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 57.49. It has decreased from 274.49 (Mar 24) to 57.49, marking a decrease of 217.00.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 70.83. It has decreased from 363.27 (Mar 24) to 70.83, marking a decrease of 292.44.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 7.65. This value is within the healthy range. It has decreased from 44.40 (Mar 24) to 7.65, marking a decrease of 36.75.
- For PBIT / Share (Rs.), as of Mar 25, the value is 5.20. This value is within the healthy range. It has decreased from 33.68 (Mar 24) to 5.20, marking a decrease of 28.48.
- For PBT / Share (Rs.), as of Mar 25, the value is 4.70. This value is within the healthy range. It has decreased from 30.94 (Mar 24) to 4.70, marking a decrease of 26.24.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 3.44. This value is within the healthy range. It has decreased from 22.90 (Mar 24) to 3.44, marking a decrease of 19.46.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 3.44. This value is within the healthy range. It has decreased from 22.90 (Mar 24) to 3.44, marking a decrease of 19.46.
- For PBDIT Margin (%), as of Mar 25, the value is 10.80. This value is within the healthy range. It has decreased from 12.22 (Mar 24) to 10.80, marking a decrease of 1.42.
- For PBIT Margin (%), as of Mar 25, the value is 7.34. This value is below the healthy minimum of 10. It has decreased from 9.27 (Mar 24) to 7.34, marking a decrease of 1.93.
- For PBT Margin (%), as of Mar 25, the value is 6.63. This value is below the healthy minimum of 10. It has decreased from 8.51 (Mar 24) to 6.63, marking a decrease of 1.88.
- For Net Profit Margin (%), as of Mar 25, the value is 4.86. This value is below the healthy minimum of 5. It has decreased from 6.30 (Mar 24) to 4.86, marking a decrease of 1.44.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 4.86. This value is below the healthy minimum of 8. It has decreased from 6.30 (Mar 24) to 4.86, marking a decrease of 1.44.
- For Return on Networth / Equity (%), as of Mar 25, the value is 5.98. This value is below the healthy minimum of 15. It has decreased from 8.34 (Mar 24) to 5.98, marking a decrease of 2.36.
- For Return on Capital Employeed (%), as of Mar 25, the value is 8.61. This value is below the healthy minimum of 10. It has decreased from 11.74 (Mar 24) to 8.61, marking a decrease of 3.13.
- For Return On Assets (%), as of Mar 25, the value is 4.24. This value is below the healthy minimum of 5. It has decreased from 5.98 (Mar 24) to 4.24, marking a decrease of 1.74.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.06. This value is within the healthy range. It has increased from 0.00 (Mar 24) to 0.06, marking an increase of 0.06.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.89. It has decreased from 0.99 (Mar 24) to 0.89, marking a decrease of 0.10.
- For Current Ratio (X), as of Mar 25, the value is 1.89. This value is within the healthy range. It has decreased from 2.00 (Mar 24) to 1.89, marking a decrease of 0.11.
- For Quick Ratio (X), as of Mar 25, the value is 1.30. This value is within the healthy range. It has increased from 1.24 (Mar 24) to 1.30, marking an increase of 0.06.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 5.29. This value is within the healthy range. It has increased from 3.82 (Mar 24) to 5.29, marking an increase of 1.47.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 23.23. This value is within the healthy range. It has increased from 21.83 (Mar 24) to 23.23, marking an increase of 1.40.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 13.56. This value is below the healthy minimum of 20. It has decreased from 14.87 (Mar 24) to 13.56, marking a decrease of 1.31.
- For Earning Retention Ratio (%), as of Mar 25, the value is 76.77. This value exceeds the healthy maximum of 70. It has decreased from 78.17 (Mar 24) to 76.77, marking a decrease of 1.40.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 86.44. This value exceeds the healthy maximum of 70. It has increased from 85.13 (Mar 24) to 86.44, marking an increase of 1.31.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 15.22. This value is within the healthy range. It has decreased from 16.19 (Mar 24) to 15.22, marking a decrease of 0.97.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 7.85. This value is within the healthy range. It has decreased from 9.35 (Mar 24) to 7.85, marking a decrease of 1.50.
- For Enterprise Value (Cr.), as of Mar 25, the value is 1,705.42. It has decreased from 1,979.48 (Mar 24) to 1,705.42, marking a decrease of 274.06.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.82. This value is below the healthy minimum of 1. It has decreased from 0.92 (Mar 24) to 0.82, marking a decrease of 0.10.
- For EV / EBITDA (X), as of Mar 25, the value is 7.59. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 7.59.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.86. This value is below the healthy minimum of 1. It has decreased from 0.99 (Mar 24) to 0.86, marking a decrease of 0.13.
- For Retention Ratios (%), as of Mar 25, the value is 76.76. This value exceeds the healthy maximum of 70. It has decreased from 78.16 (Mar 24) to 76.76, marking a decrease of 1.40.
- For Price / BV (X), as of Mar 25, the value is 1.06. This value is within the healthy range. It has decreased from 1.32 (Mar 24) to 1.06, marking a decrease of 0.26.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.86. This value is below the healthy minimum of 1. It has decreased from 0.99 (Mar 24) to 0.86, marking a decrease of 0.13.
- For EarningsYield, as of Mar 25, the value is 0.05. This value is below the healthy minimum of 5. It has decreased from 0.06 (Mar 24) to 0.05, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in IOL Chemicals & Pharmaceuticals Ltd:
- Net Profit Margin: 4.86%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 8.61% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 5.98% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 7.85
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.3
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 21.2 (Industry average Stock P/E: 51.81)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.06
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 4.86%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Village & Post Office Handiaya, Barnala Punjab 148107 | investor@iolcp.com http://www.iolcp.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Rajender Mohan Malla | Chairman & Ind.Director |
| Mr. Varinder Gupta | Managing Director |
| Mr. Vikas Gupta | Joint Managing Director |
| Mr. Abhiraj Gupta | Executive Director |
| Mr. Kushal Kumar Rana | Director - Works |
| Mr. Harpal Singh | Independent Director |
| Mr. Sharad Tyagi | Independent Director |
| Mr. Rajni Jha | Independent Director |
FAQ
What is the intrinsic value of IOL Chemicals & Pharmaceuticals Ltd?
IOL Chemicals & Pharmaceuticals Ltd's intrinsic value (as of 12 December 2025) is 62.66 which is 25.40% lower the current market price of 84.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 2,465 Cr. market cap, FY2025-2026 high/low of 127/57.5, reserves of ₹1,692 Cr, and liabilities of 2,413 Cr.
What is the Market Cap of IOL Chemicals & Pharmaceuticals Ltd?
The Market Cap of IOL Chemicals & Pharmaceuticals Ltd is 2,465 Cr..
What is the current Stock Price of IOL Chemicals & Pharmaceuticals Ltd as on 12 December 2025?
The current stock price of IOL Chemicals & Pharmaceuticals Ltd as on 12 December 2025 is 84.0.
What is the High / Low of IOL Chemicals & Pharmaceuticals Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of IOL Chemicals & Pharmaceuticals Ltd stocks is 127/57.5.
What is the Stock P/E of IOL Chemicals & Pharmaceuticals Ltd?
The Stock P/E of IOL Chemicals & Pharmaceuticals Ltd is 21.2.
What is the Book Value of IOL Chemicals & Pharmaceuticals Ltd?
The Book Value of IOL Chemicals & Pharmaceuticals Ltd is 59.7.
What is the Dividend Yield of IOL Chemicals & Pharmaceuticals Ltd?
The Dividend Yield of IOL Chemicals & Pharmaceuticals Ltd is 0.95 %.
What is the ROCE of IOL Chemicals & Pharmaceuticals Ltd?
The ROCE of IOL Chemicals & Pharmaceuticals Ltd is 8.86 %.
What is the ROE of IOL Chemicals & Pharmaceuticals Ltd?
The ROE of IOL Chemicals & Pharmaceuticals Ltd is 6.13 %.
What is the Face Value of IOL Chemicals & Pharmaceuticals Ltd?
The Face Value of IOL Chemicals & Pharmaceuticals Ltd is 2.00.